WO2005085469A3 - Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1) - Google Patents

Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1) Download PDF

Info

Publication number
WO2005085469A3
WO2005085469A3 PCT/EP2005/001925 EP2005001925W WO2005085469A3 WO 2005085469 A3 WO2005085469 A3 WO 2005085469A3 EP 2005001925 W EP2005001925 W EP 2005001925W WO 2005085469 A3 WO2005085469 A3 WO 2005085469A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
rock1
rho
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/001925
Other languages
French (fr)
Other versions
WO2005085469A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2005085469A2 publication Critical patent/WO2005085469A2/en
Publication of WO2005085469A3 publication Critical patent/WO2005085469A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human ROCK1 which is associated with cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of ROCK1 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/001925 2004-03-09 2005-02-24 Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1) WO2005085469A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005544.4 2004-03-09
EP04005544 2004-03-09

Publications (2)

Publication Number Publication Date
WO2005085469A2 WO2005085469A2 (en) 2005-09-15
WO2005085469A3 true WO2005085469A3 (en) 2005-11-24

Family

ID=34917168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001925 WO2005085469A2 (en) 2004-03-09 2005-02-24 Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)

Country Status (1)

Country Link
WO (1) WO2005085469A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057252A1 (en) 2005-12-27 2007-11-21 Alcon Mfg Ltd INHIBITION OF RHO KINASE MEDIATED BY ARNI FOR THE TREATMENT OF EYE DISORDERS
WO2016057306A1 (en) 2014-10-06 2016-04-14 University Of Houston Rho associated kinase (rock) inhibitors and their use in treating disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834290A (en) * 1993-06-18 1998-11-10 Astra Aktiebolag Recombinant stratum corneum chymotryptic enzyme (SCCE)
US6099823A (en) * 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO2003080125A2 (en) * 2002-03-22 2003-10-02 Glaxo Group Limited Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834290A (en) * 1993-06-18 1998-11-10 Astra Aktiebolag Recombinant stratum corneum chymotryptic enzyme (SCCE)
US6099823A (en) * 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
WO2003080125A2 (en) * 2002-03-22 2003-10-02 Glaxo Group Limited Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HU ERDING ET AL: "Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) SEP 2003, vol. 4, no. 9, September 2003 (2003-09-01), pages 1065 - 1075, XP009050277, ISSN: 1472-4472 *
SUYAMA EIGO ET AL: "Identification of genes responsible for cell migration by a library of randomized ribozymes.", CANCER RESEARCH, vol. 63, no. 1, 1 January 2003 (2003-01-01), pages 119 - 124, XP002334877, ISSN: 0008-5472 *
UEHATA M ET AL: "Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 389, 30 October 1997 (1997-10-30), pages 990 - 994, XP002131752, ISSN: 0028-0836 *
ZHOU JIN ET AL: "Gene expression profiles at different stages of human esophageal squamous cell carcinoma.", WORLD JOURNAL OF GASTROENTEROLOGY : WJG. JAN 2003, vol. 9, no. 1, January 2003 (2003-01-01), pages 9 - 15, XP002334878, ISSN: 1007-9327 *

Also Published As

Publication number Publication date
WO2005085469A2 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2006010517A3 (en) Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005114207A3 (en) Diagnostics and therapeutics for diseases associated with aminopeptidase n (anpep)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005022146A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005085469A3 (en) Diagnostics and therapeutics for diseases associated with rho-associated protein kinase 1 (rock1)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2006013013A3 (en) Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2006013014A3 (en) Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal)
WO2005026719A3 (en) Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3)
WO2005095631A3 (en) Diagnostics and therapeutics for diseases associated with mixed lineage kinase 4 alpha (mlk4 alpha)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase